GlassScriptPhysician profile
Ivan Picado Martinez
NPI 1023014800
$11,343.04
in general payments reported to CMS, 2019-2025
40 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,747 · 2020: $1,314 · 2021: $1,823 · 2022: $1,264 · 2023: $1,031 · 2024: $908 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,566.15 | 2019-2022 | |
| Lilly USA, LLC | $1,330.37 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Abbvie INC. | $1,178.66 | 2019-2025 | |
| Amgen INC. | $1,053.90 | 2019-2025 | Repatha, Tepezza |
| Sanofi-Aventis U.S. LLC | $723.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $604.11 | 2019-2022 | |
| Novo Nordisk INC | $581.75 | 2019-2025 | Ozempic, Rybelsus |
| Mannkind Corporation | $532.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.48 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $456.65 | 2021-2025 | |
| Corcept Therapeutics | $429.34 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $391.74 | 2019-2023 | Steglatro, Belsomra |
| Antares Pharma, INC. | $359.58 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Janssen Pharmaceuticals, INC | $247.47 | 2019 | |
| Abbott Laboratories | $243.67 | 2020-2025 | Freestyle Libre 3 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.